EW Jun 2024 65.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 10:30AM EDT
Loading interactive chart…
- Zacks
HOLX vs. EW: Which Stock Should Value Investors Buy Now?
HOLX vs. EW: Which Stock Is the Better Value Option?
- Zacks
BD (BDX) Inks Buyout Deal to Expand Smart Connected Care Suite
BD's (BDX) latest agreement is likely to unlock new future value-creation opportunities and expand its portfolio of smart connected care solutions.
- Business Wire
Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR
NEW YORK, June 05, 2024--Edwards Lifesciences (NYSE: EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR) patients with a small annulus. Through five-year follow up of more than 1,300 low and intermediate risk SAPIEN 3 valve patients there were excellent clinical outcomes and valve durability irrespective of the patient’s annulus size or sex. These data were presented during the late-breaking clinical
© 2024 Yahoo. All rights reserved.